Device Trial Radar · NCT05460715
The Medacta Quadra-P Anteverted Study
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Jul 30, 2021
Primary completion
Jul 2032
Study completion Jul 2032
Sponsor
- Lead sponsor
- Medacta International SANot on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 15, 2022
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Post-Marketing Surveillance of Quadra-P anteverted stem prosthesis.
Conditions
- Arthrosis
- Traumatic Arthritis
- Rheumatoid Polyarthritis
- Congenital Hip Dysplasia
- Avascular Necrosis of the Femoral Head
Interventions
Quadra P antevertedDevice
* Assess clinical performance by Harris Hip score collected during preoperative and postoperative visits at 3 months, 1, 2, 5, 7 and 10 years. * Assess radiological performance by standard radiographic examination performed before surgery, after surgery before discharge and during postoperative visits at 3 months, 1, 2, 5, 7 and 10 years. * Assessing the patient's perception of the prosthetic joint by means of FJS questionnaire collected during the preoperative visit and postoperative visits at 3 months and at 1, 2, 5, 7 and 10 years after surgery. * Assessment of functional recovery by gait analysis study * Collect the rate of complications throughout the course of the study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the 10-year survival of the anteverted Quadra-P stemTime frame: 10 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Istituto Ortopedico Franco Scalabrino
Messina, Messina, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.